Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170683 | 0.80 | TSHR (0.35) | TSHRALDH1A1SMN1; SMN2MAPTFAAH | |
| SCHEMBL8593888 | 0.80 | TSHR (0.35) | TSHRSMN1; SMN2MAPTFAAHKMT2A | |
| Water SCHEMBL10920606 | 0.78 | TSHR (0.34) | TSHRALDH1A1SMN1; SMN2MAPTFAAH | |
| SCHEMBL5954434 | 0.77 | PKM (0.35) | TSHRALDH1A1SMN1; SMN2MAPTFAAH | |
| Hydrochloric Acid SCHEMBL10962377 | 0.75 | PKM (0.34) | TSHRALDH1A1SMN1; SMN2MAPTFAAH | |
| SCHEMBL2297015 | 0.72 | — | — | |
| SCHEMBL22788816 | 0.70 | GRM4 (0.30) | — | |
| SCHEMBL22790562 | 0.70 | MAOA (0.34) | — | |
| SCHEMBL7600761 | 0.69 | KMT2A (0.33) | TSHRSMN1; SMN2MAPTFAAHKMT2A | |
| SCHEMBL1007132 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | TSHR 74/4885ALDH1A1 2567/4885SMN1; SMN2 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.